Lung Cancer Screening Software Market Size, Share & Trends Analysis Report By Region (North America (U.S., Canada, Mexico), APAC, Europe, Latin America, MEA), And Segment Forecasts, 2024

Description

Lung Cancer Screening Software Market Growth & Trends:

The global lung cancer screening software market size is expected to reach USD 45.0 million by 2030, registering a CAGR of 6.9% from 2024 to 2030, according to a new report by Grand View Research, Inc. Growing incidence of lung cancer and rise in implementation of lung cancer screening programs across the globe are some of the significant factors driving the market growth. According to Globocan estimates, about 160,068 new cases of lung cancer were reported in South East Asian region in 2018.

A number of clinical trials, studies, and demonstration projects are being conducted around the world to evaluate the effectiveness of lung cancer screening programs. For instance, in 2017, Cancer Care Ontario launched a screening pilot trial for people at high risk. Favorable government initiatives for successful implementation of such programs and increasing awareness about the disease screening are also likely to contribute to the market growth in the coming years.

Lung cancer screening programs are widely adopted by hospitals and radiological centers in U.S. However, they are usually performed as a part of national or provisional screening program outside the country. In case of Latin America and Middle Eastern countries, limited availability of resources, restricted funding, low awareness levels, and lack of trained personnel are some of the factors that impede market growth.

Lung Cancer Screening Software Market Report Highlights:

In 2023, North America accounted for the highest revenue share owing to various lung cancer screening programs and favorable reimbursement scenario in the region
Asia Pacific is expected to be the fastest-growing regional market over the forecast period
This is attributed to the increasing cases of lung cancer and rise in the number of screening trials & studies for the disease

Product Code: GVR-3-68038-303-4

Chapter 1. Methodology and Scope

1.1. Market Segmentation and Scope
1.2. Market Definitions
1.3. Research Methodology
- 1.3.1. Information Procurement
- 1.3.2. Information or Data Analysis
- 1.3.3. Market Formulation & Data Visualization
- 1.3.4. Data Validation & Publishing
1.4. Research Scope and Assumptions
- 1.4.1. List of Data Sources

Chapter 2. Executive Summary

2.1. Market Outlook
2.2. Segment Outlook
2.3. Competitive Insights

Chapter 3. Lung Cancer Screening Software Market Variables, Trends, & Scope

3.1. Market Introduction/Lineage Outlook
3.2. Market Size and Growth Prospects (USD Thousands)
3.3. Market Dynamics
- 3.3.1. Market Drivers Analysis
- 3.3.2. Market Restraints Analysis
3.4. Lung Cancer Screening Software Market Analysis Tools
- 3.4.1. Porter's Analysis
  - 3.4.1.1. Bargaining power of the suppliers
  - 3.4.1.2. Bargaining power of the buyers
  - 3.4.1.3. Threats of substitution
  - 3.4.1.4. Threats from new entrants
  - 3.4.1.5. Competitive rivalry
- 3.4.2. PESTEL Analysis
  - 3.4.2.1. Political landscape
  - 3.4.2.2. Economic and Social landscape
  - 3.4.2.3. Technological landscape
  - 3.4.2.4. Environmental landscape
  - 3.4.2.5. Legal landscape

Chapter 4. Lung Cancer Screening Software Market: Regional Estimates & Trend Analysis

4.1. Lung Cancer Screening Software Market Share, By Region, 2023 & 2030, USD Thousands
4.2. North America
- 4.2.1. North America Lung Cancer Screening Software Market Estimates and Forecasts, 2018 - 2030 (USD Thousands)
- 4.2.2. U.S.
  - 4.2.2.1. U.S. Lung Cancer Screening Software Market Estimates and Forecasts, 2018 - 2030 (USD Thousands)
- 4.2.3. Canada
  - 4.2.3.1. Canada Lung Cancer Screening Software Market Estimates and Forecasts, 2018 - 2030 (USD Thousands)
- 4.2.4. Mexico
  - 4.2.4.1. Mexico Lung Cancer Screening Software Market Estimates and Forecasts, 2018 - 2030 (USD Thousands)
4.3. Europe
- 4.3.1. Europe Lung Cancer Screening Software Market Estimates and Forecasts, 2018 - 2030 (USD Thousands)
- 4.3.2. U.K.
  - 4.3.2.1. U.K. Lung Cancer Screening Software Market Estimates and Forecasts, 2018 - 2030 (USD Thousands)
- 4.3.3. Germany
  - 4.3.3.1. Germany Lung Cancer Screening Software Market Estimates and Forecasts, 2018 - 2030 (USD Thousands)
- 4.3.4. France
  - 4.3.4.1. France Lung Cancer Screening Software Market Estimates and Forecasts, 2018 - 2030 (USD Thousands)
- 4.3.5. Spain
  - 4.3.5.1. Spain Lung Cancer Screening Software Market Estimates and Forecasts, 2018 - 2030 (USD Thousands)
- 4.3.6. Italy
  - 4.3.6.1. Italy Lung Cancer Screening Software Market Estimates and Forecasts, 2018 - 2030 (USD Thousands)
- 4.3.7. Russia
  - 4.3.7.1. Russia Lung Cancer Screening Software Market Estimates and Forecasts, 2018 - 2030 (USD Thousands)
4.4. Asia Pacific
- 4.4.1. Asia Pacific Lung Cancer Screening Software Market Estimates and Forecasts, 2018 - 2030 (USD Thousands)
- 4.4.2. China
  - 4.4.2.1. China Lung Cancer Screening Software Market Estimates and Forecasts, 2018 - 2030 (USD Thousands)
- 4.4.3. Japan
  - 4.4.3.1. Japan Lung Cancer Screening Software Market Estimates and Forecasts, 2018 - 2030 (USD Thousands)
- 4.4.4. Australia
  - 4.4.4.1. Australia Lung Cancer Screening Software Market Estimates and Forecasts, 2018 - 2030 (USD Thousands)
4.5. Latin America
- 4.5.1. Latin America Lung Cancer Screening Software Market Estimates and Forecasts, 2018 - 2030 (USD Thousands)
- 4.5.2. Brazil
  - 4.5.2.1. Brazil Lung Cancer Screening Software Market Estimates and Forecasts, 2018 - 2030 (USD Thousands)
4.6. Middle East and Africa
- 4.6.1. Middle East and Africa Lung Cancer Screening Software Market Estimates and Forecasts, 2018 - 2030 (USD Thousands)
- 4.6.2. South Africa
  - 4.6.2.1. South Africa Lung Cancer Screening Software Market Estimates and Forecasts, 2018 - 2030 (USD Thousands)

Chapter 5. Competitive Landscape

5.1. Recent Developments & Impact Analysis by Key Market Participants
5.2. Company Categorization
5.3. Company Heat Map Analysis
5.4. Company Profiles
- 5.4.1. Nuance Communications, Inc.
  - 5.4.1.1. Participant's Overview
  - 5.4.1.2. Financial Performance
  - 5.4.1.3. Product Benchmarking
  - 5.4.1.4. Recent Developments/ Strategic Initiatives
- 5.4.2. MRS
  - 5.4.2.1. Participant's Overview
  - 5.4.2.2. Financial Performance
  - 5.4.2.3. Product Benchmarking
  - 5.4.2.4. Recent Developments/ Strategic Initiatives
- 5.4.3. Voxel Cloud
  - 5.4.3.1. Participant's Overview
  - 5.4.3.2. Financial Performance
  - 5.4.3.3. Product Benchmarking
  - 5.4.3.4. Recent Developments/ Strategic Initiatives
- 5.4.4. Eon
  - 5.4.4.1. Participant's Overview
  - 5.4.4.2. Financial Performance
  - 5.4.4.3. Product Benchmarking
  - 5.4.4.4. Recent Developments/ Strategic Initiatives
- 5.4.5. Koninklijke Philips N.V.
  - 5.4.5.1. Participant's Overview
  - 5.4.5.2. Financial Performance
  - 5.4.5.3. Product Benchmarking
  - 5.4.5.4. Recent Developments/ Strategic Initiatives
- 5.4.6. Siemens Healthineers AG
  - 5.4.6.1. Participant's Overview
  - 5.4.6.2. Financial Performance
  - 5.4.6.3. Product Benchmarking
  - 5.4.6.4. Recent Developments/ Strategic Initiatives
- 5.4.7. PENRAD
  - 5.4.7.1. Participant's Overview
  - 5.4.7.2. Financial Performance
  - 5.4.7.3. Product Benchmarking
  - 5.4.7.4. Recent Developments/ Strategic Initiatives
- 5.4.8. MagView
  - 5.4.8.1. Participant's Overview
  - 5.4.8.2. Financial Performance
  - 5.4.8.3. Product Benchmarking
  - 5.4.8.4. Recent Developments/ Strategic Initiatives
- 5.4.9. FUJIFILM Holdings Corporation
  - 5.4.9.1. Participant's Overview
  - 5.4.9.2. Financial Performance
  - 5.4.9.3. Product Benchmarking
  - 5.4.9.4. Recent Developments/ Strategic Initiatives
- 5.4.10. Medtronic
  - 5.4.10.1. Participant's Overview
  - 5.4.10.2. Financial Performance
  - 5.4.10.3. Product Benchmarking
  - 5.4.10.4. Recent Developments/ Strategic Initiatives

Lung Cancer Screening Software Market Size, Share & Trends Analysis Report By Region (North America (U.S., Canada, Mexico), APAC, Europe, Latin America, MEA), And Segment Forecasts, 2024 - 2030